173 related articles for article (PubMed ID: 30338914)
41. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
[TBL] [Abstract][Full Text] [Related]
42. Aberrant miR199a-5p/caveolin1/PPARα axis in hepatic steatosis.
Li B; Zhang Z; Zhang H; Quan K; Lu Y; Cai D; Ning G
J Mol Endocrinol; 2014 Dec; 53(3):393-403. PubMed ID: 25312970
[TBL] [Abstract][Full Text] [Related]
43. miR-26a Potentially Contributes to the Regulation of Fatty Acid and Sterol Metabolism In Vitro Human HepG2 Cell Model of Nonalcoholic Fatty Liver Disease.
Ali O; Darwish HA; Eldeib KM; Abdel Azim SA
Oxid Med Cell Longev; 2018; 2018():8515343. PubMed ID: 30402207
[TBL] [Abstract][Full Text] [Related]
44. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease.
Shan W; Gao L; Zeng W; Hu Y; Wang G; Li M; Zhou J; Ma X; Tian X; Yao J
Cell Death Dis; 2015 Jul; 6(7):e1833. PubMed ID: 26203862
[TBL] [Abstract][Full Text] [Related]
45. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
[TBL] [Abstract][Full Text] [Related]
46. A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism.
Xu Y; Zalzala M; Xu J; Li Y; Yin L; Zhang Y
Nat Commun; 2015 Jun; 6():7466. PubMed ID: 26100857
[TBL] [Abstract][Full Text] [Related]
47. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease.
Ding J; Li M; Wan X; Jin X; Chen S; Yu C; Li Y
Sci Rep; 2015 Sep; 5():13729. PubMed ID: 26330104
[TBL] [Abstract][Full Text] [Related]
48. MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease.
Wang XC; Zhan XR; Li XY; Yu JJ; Liu XM
World J Gastroenterol; 2014 Dec; 20(47):17914-23. PubMed ID: 25548489
[TBL] [Abstract][Full Text] [Related]
49. Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease.
Soronen J; Yki-Järvinen H; Zhou Y; Sädevirta S; Sarin AP; Leivonen M; Sevastianova K; Perttilä J; Laurila PP; Sigruener A; Schmitz G; Olkkonen VM
Physiol Rep; 2016 Jan; 4(1):. PubMed ID: 26733244
[TBL] [Abstract][Full Text] [Related]
50. A negative feedback loop between microRNA-378 and Nrf1 promotes the development of hepatosteatosis in mice treated with a high fat diet.
Zhang T; Zhao X; Steer CJ; Yan G; Song G
Metabolism; 2018 Aug; 85():183-191. PubMed ID: 29625129
[TBL] [Abstract][Full Text] [Related]
51. MiR-451a attenuates free fatty acids-mediated hepatocyte steatosis by targeting the thyroid hormone responsive spot 14 gene.
Zeng N; Huang R; Li N; Jiang H; Li R; Wang F; Chen W; Xia M; Wang Q
Mol Cell Endocrinol; 2018 Oct; 474():260-271. PubMed ID: 29604329
[TBL] [Abstract][Full Text] [Related]
52. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
53. Induction of miR-96 by Dietary Saturated Fatty Acids Exacerbates Hepatic Insulin Resistance through the Suppression of INSR and IRS-1.
Yang WM; Min KH; Lee W
PLoS One; 2016; 11(12):e0169039. PubMed ID: 28036389
[TBL] [Abstract][Full Text] [Related]
54. Regulation of insulin resistance by targeting the insulin-like growth factor 1 receptor with microRNA-122-5p in hepatic cells.
Dong L; Hou X; Liu F; Tao H; Zhang Y; Zhao H; Song G
Cell Biol Int; 2019 May; 43(5):553-564. PubMed ID: 30958584
[TBL] [Abstract][Full Text] [Related]
55. Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease.
Zhang H; Yang L; Wang Y; Huang W; Li Y; Chen S; Song G; Ren L
Life Sci; 2020 Sep; 257():118090. PubMed ID: 32679144
[TBL] [Abstract][Full Text] [Related]
56. MicroRNA-26a-CD36 signaling pathway: Pivotal role in lipid accumulation in hepatocytes induced by PM
Ding D; Ye G; Lin Y; Lu Y; Zhang H; Zhang X; Hong Z; Huang Q; Chi Y; Chen J; Dong S
Environ Pollut; 2019 May; 248():269-278. PubMed ID: 30798028
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
Wu H; Zhang T; Pan F; Steer CJ; Li Z; Chen X; Song G
J Hepatol; 2017 Apr; 66(4):816-824. PubMed ID: 28025059
[TBL] [Abstract][Full Text] [Related]
58. Hepatic miR-125b inhibits insulin signaling pathway by targeting PIK3CD.
Du X; Li X; Chen L; Zhang M; Lei L; Gao W; Shi Z; Dong Y; Wang Z; Li X; Liu G
J Cell Physiol; 2018 Aug; 233(8):6052-6066. PubMed ID: 29319168
[TBL] [Abstract][Full Text] [Related]
59. Effect and possible mechanisms of dioscin on ameliorating metabolic glycolipid metabolic disorder in type-2-diabetes.
Xu LN; Yin LH; Jin Y; Qi Y; Han X; Xu YW; Liu KX; Zhao YY; Peng JY
Phytomedicine; 2020 Feb; 67():153139. PubMed ID: 31881477
[TBL] [Abstract][Full Text] [Related]
60. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications.
Di Mauro S; Ragusa M; Urbano F; Filippello A; Di Pino A; Scamporrino A; Pulvirenti A; Ferro A; Rabuazzo AM; Purrello M; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1129-1139. PubMed ID: 27756518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
